首页> 美国卫生研究院文献>Cancers >STAT3 and STAT5 Activation in Solid Cancers
【2h】

STAT3 and STAT5 Activation in Solid Cancers

机译:实体癌中的STAT3和STAT5激活

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models.
机译:信号转导和转录激活子(STAT)3和5蛋白被许多细胞因子受体激活,以调节特定的基因表达和线粒体功能。它们在癌症中的作用很大程度上取决于上下文,因为它们都可以充当癌基因和抑癌基因。我们在这里回顾了STAT3 / 5激活在实体癌中的作用,并总结了它们与癌症患者生存率的关系。 STAT3 / 5信号传导的致癌活性的分子机制包括控制细胞周期和细胞死亡的基因的调节。然而,最近的进展也突出了STAT3 / 5靶基因介导炎症和干性的关键作用。另外,STAT3线粒体功能是转化所必需的。另一方面,STAT3 / 5信号通路上有几种抑制或激活肿瘤的途径,包括酪氨酸磷酸酶,激活的STAT3的相扑连接酶蛋白抑制剂(PIAS3),E3泛素连接酶TATA因子调节因子/雄激素受体-共激活因子160 kDa(TMF / ARA160),miRNA miR-124和miR-1181,替代阅读框19蛋白(p19ARF)/ p53途径以及细胞因子信号1和3的抑制因子(SOCS1 / 3)。癌症突变和表观遗传学改变可能会改变致癌活性与STAT3 / 5信号传导相关的肿瘤抑制活性之间的平衡,从而解释了在人类癌症和动物模型中它们与肿瘤进展的背景相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号